Axogen
Specializes in peripheral nerve repair devices
Material Control Technician
+ Annual performance bonus
May require travel to and work at other Axogen locations as needed.
About the job
- A high school diploma or equivalent.
- A valid driver’s license.
- Proficiency in current processes and the ability to effectively assist with training.
- At least one additional cross-functional support skill, such as environmental monitoring or inventory recording.
- Ability to make decisions based on awareness of area operations.
- Written and verbal communication, interpersonal, and analytical troubleshooting skills.
- Ability to work with people under high pressure and in a constantly changing environment.
- Ability to travel to and work at other Axogen locations as needed.
- Ability to exert up to 50 pounds of force occasionally, up to 30 pounds frequently, and/or up to 10 pounds constantly to lift, carry, push, pull, or otherwise move objects.
- Mental acuity, visual acuity, prolonged walking and standing, repetitive motion, speaking, grasping, manual dexterity, talking, and hearing.
- Ability to handle potentially infectious human tissue, chemicals, and hazardous and non-hazardous waste using required precautions and personal protective equipment.
- Ability to sit for two to four hours or more while debriding and evaluating human tissue and wear surgical magnification loupes for two to four hours or more.
- Receive, store, pick, and ship raw materials, supplies, and finished products according to internal and external requirements.
- Handle, move, and store non-hazardous and hazardous materials.
- Coordinate the timely and accurate flow of materials from warehouse inventory to work-in-process and production areas.
- Coordinate the timely and accurate flow of finished products to support shipments to customers and other destinations.
- Implement and maintain the effectiveness of the quality system, including proper first-in, first-out practices.
- Store, issue, or prepare warehouse materials while verifying lot number, quantity, release status, and other unique identifiers using good documentation practices.
- Check materials against packing lists, invoices, freight bills, and other pertinent documentation for conformity and accuracy.
- Deliver materials to processing areas in a timely manner and maintain proper first-in, first-out flow of raw materials and other time-sensitive supplies.
- Maintain organized workspaces in tissue, supplies, and finished-goods warehouse areas.
- Maintain accurate records and reconcile inventory errors.
- Follow personal safety requirements and applicable FDA current Good Manufacturing Practice, USDA, OSHA, Axogen, cleanroom, processing, cleaning, documentation, and standard operating procedure requirements.
- Supply materials to functional areas and move materials to and from dock areas to maintain efficient shipping and receiving operations.
- Participate in daily stand-up meetings, continuous improvement projects, Kanban practices, and 5S initiatives.
- Cover the assigned call schedule, including holidays and weekends.
- Perform other duties as directed by the supervisor and work in other Axogen roles or departments as needed.
- Experience in a current Good Manufacturing Practice environment.
- Forklift certification.
- Enterprise resource planning system experience.
About the company
Axogen develops and sells surgical solutions specifically for repairing peripheral nerve damage. The company’s products, such as the Avance Nerve Graft, work by using processed human donor tissue to bridge gaps in severed nerves, while its Axoguard line provides protective wraps and connectors to shield nerves during the healing process. Unlike traditional methods that require a second surgery to harvest a patient's own healthy nerve, Axogen provides ready-to-use grafts that eliminate additional surgical trauma and potential lasting damage at a donor site. The company's goal is to provide surgeons with a comprehensive platform of clinically proven tools to restore nerve function and improve the quality of life for patients with nerve injuries.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Alachua, Florida
Founded
2002
Get referred to Axogen
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $69.7 million, up 23.1%, and guidance rose to $279 million.
- Commercial payer coverage reached about 86% of U.S. lives, expanding reimbursement reach.
- CMS proposed 2027 payment increases and REPOSE, Nerve-RESTORE, and Trace broaden future demand.
What critics are saying
- Aetna still blocks Avance access; delayed coverage restrains 2026 sales expansion.
- Breast reconstruction mix compressed Q2 2026 gross margin to 72.7%, pressuring profitability.
- A cheaper autograft standard and competing biologics threaten Axogen's premium pricing and market share.
What makes Axogen unique
- Avance Nerve Graft remains the only FDA-approved implantable biologic nerve allograft.
- Axogen built direct surgeon relationships across extremity, breast, oral, and head-and-neck procedures.
- The Trace Biosciences investment extends Axogen into nerve visualization before injury and repair.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Paid Vacation
Paid Holidays
Employee Stock Purchase Plan
Tuition Reimbursement
Paid Parental Leave
Paid Caregiver Leave
Basic Life Insurance
Supplemental Life Insurance
Disability Insurance
Growth & Insights and Company News
6 month growth
↑ 14%1 year growth
↑ 14%2 year growth
↑ 14%Axogen reported second-quarter 2026 sales of $69.73 million and a net loss of $1.52 million. The company raised its full-year 2026 revenue outlook to at least $279 million, implying revenue growth of at least 24%. Breast reconstruction became a key driver, accounting for more than half of quarterly revenue. This growth is reshaping Axogen's product mix and margin profile. The upgraded guidance underscores momentum in procedure adoption. However, investors face ongoing risks from margin pressure, higher operating costs, and potential reimbursement uncertainty. Axogen's narrative projects $395.3 million revenue and $16.1 million earnings by 2029, requiring 18.4% annual revenue growth. Simply Wall St Community members value the shares between $47.85 and $51.67.
Trace Biosciences has received a strategic investment from Axogen, the global leader in surgical solutions for peripheral nerve restoration, to advance its Nerve Trace imaging technology through clinical development. The investment forms part of Trace's Series A financing round. Nerve Trace is a near-infrared fluorescence imaging technology that provides real-time visualisation of nerves during surgery, enabling surgeons to identify and avoid nerves obscured by surrounding tissue and to assess injured nerves more precisely. Trace's lead candidate, Nerve Trace Dx, received FDA clearance for its Investigational New Drug application in December 2025 and has begun Phase I clinical trials. Proceeds will support Phase II and III trials towards a New Drug Application. "This investment strengthens our ability to advance Nerve Trace through clinical work ahead," said Connor Barth, Co-Founder and CEO of Trace Biosciences.
Axogen's strategic investment puts spotlight on Trace's Nerve Imaging technology. 29 July 2026, 8:46 AM Landmark collaboration promises next-generation nerve visualization in surgery. Axogen (NASDAQ:AXGN), the recognized leader in peripheral nerve repair solutions, has taken a strategic leap by investing in Trace Biosciences' Series A round. Trace is developing the Nerve Trace, a novel near-infrared fluorescence imaging agent designed to give surgeons real-time, direct visualization of nerves during procedures - a capability that could fundamentally alter the standard of care. Why this technology stands out: making nerves visible, protecting function. One of the biggest challenges in nerve surgery is that vital structures are frequently hidden by tissue, increasing the risk of accidental damage. Trace's Nerve Trace aims to solve this problem at its root. By lighting up nerves in real time, it gives surgeons the ability to identify, avoid, or precisely repair them - even when normal vision fails. The technology could reduce complications and improve surgical outcomes for patients recovering from trauma or undergoing complex procedures. Trace Biosciences is already moving forward. Its lead candidate, Nerve Trace Dx, began Phase I clinical trials after FDA clearance of its IND in December 2025. The investment by Axogen will power Phase II and III trials, ultimately aiming for regulatory approval and commercial launch. | Key Technology | Stage | Intended Benefit | Funding Purpose | | Nerve Trace Dx (Real-Time Nerve Imaging) | Phase I Clinical Trial (Post-IND Clearance) | Improved nerve identification and repair in surgery | Advance to Phase II & III trials | Strategic rationale: aligning innovation with standard of care. For Axogen, the investment is more than financial - it's mission-driven. As CEO Michael Dale puts it, "Improving nerve care starts with being able to see the nerve. You can't treat what you can't see." This collaboration is a logical extension of Axogen's portfolio, which already includes products such as Avance(R) Nerve Graft and Axoguard(R) Nerve Connector for nerve reconstruction. Integrating imaging into the surgical workflow complements Axogen's goal of restoring nerve function as a routine standard. Implications for surgeons and patients: raising the bar for nerve care. Trace Biosciences and Axogen are betting that real-time nerve visualization can become as integral to surgery as advanced imaging is today for other fields of medicine. Surgeons could soon have a tool that not only helps prevent nerve injury, but also facilitates more precise repairs. The partnership leverages Trace's innovation and Axogen's commercial and clinical expertise, potentially accelerating adoption if upcoming trials prove successful. Key takeaways: A strategic bet on smarter, safer surgeries. This investment signals that industry leaders see significant value - and a clinical need - for nerve-specific imaging in surgery. For investors and clinicians, it's a trend worth following. The pace of Trace's clinical progress and Axogen's hands-on involvement may set a roadmap for broader shifts in surgical care standards. Watch this collaboration as it unfolds; it could fundamentally improve patient outcomes and surgical precision in the years ahead. Contact Information: If you have feedback or concerns about the content, please feel free to reach out to Market Chameleon via email at [email protected]. About the Publisher - Marketchameleon.com: Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. Market Chameleon leverage extensive data, models, and analytics to provide valuable insights into these markets. Its primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards. NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com. The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information. Disclosure: This article was generated with the assistance of AI
AxoGen, a peripheral nerve repair company, said its growth strategy remains intact despite uncertainty around the timing of recent reimbursement wins. CEO Michael Dale said the company expects positive impacts from coverage decisions and a 40% CMS outpatient rate increase effective January 2026, but cannot yet quantify the financial benefit. Dale said adoption requires provider education and contract negotiations, which take time. Aetna remains the last major payer pending a decision, expected by end of June. The company maintained its double-digit growth outlook and reported 27% first-quarter growth. Gross margin is expected to bottom in the second quarter before improving. AxoGen plans to release clinical data from a prostate nerve repair pilot in the second half of 2026, which could inform future commercialisation plans.
Axogen, a medical technology company, has raised analyst price targets following first-quarter results that beat revenue forecasts. The company reported revenues of $61 million, exceeding expectations by 6.4%, whilst statutory losses of $0.38 per share were in line with predictions. Following the results, nine analysts now predict 2026 revenues of $270.9 million, representing 14% growth compared to the previous 12 months. Losses are expected to fall 35% to $0.39 per share. The average price target rose 23% to $41.22, suggesting analysts view current losses as temporary. Analysts forecast Axogen's revenue will grow at 19% annually through 2026, significantly faster than its historical 14% growth rate and the wider industry's projected 7.9% annual growth.